Experimental treatments for HIV-infected patients.
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives; D000998:Antiviral Agents / Q000627:therapeutic use*; D005944:Glucosamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019302:HIV Envelope Protein gp160; D006679:HIV Seropositivity / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D011994:Recombinant Proteins; D012191:Retroviridae Proteins / Q000627:therapeutic use*; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014759:Viral Envelope Proteins / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use*
D000998:Antiviral Agents; D019302:HIV Envelope Protein gp160; D011994:Recombinant Proteins; D012191:Retroviridae Proteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; D017485:1-Deoxynojirimycin; C059896:miglustat; D005944:Glucosamine